Compare JJSF & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | MIRM |
|---|---|---|
| Founded | 1971 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 3.4B |
| IPO Year | N/A | 2019 |
| Metric | JJSF | MIRM |
|---|---|---|
| Price | $92.51 | $80.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $138.33 | $92.45 |
| AVG Volume (30 Days) | 293.3K | ★ 790.7K |
| Earning Date | 02-02-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.36 | N/A |
| Revenue | ★ $3,166,466,000.00 | $471,794,000.00 |
| Revenue This Year | N/A | $53.78 |
| Revenue Next Year | $2.24 | $19.91 |
| P/E Ratio | $27.51 | ★ N/A |
| Revenue Growth | 0.54 | ★ 53.66 |
| 52 Week Low | $80.67 | $36.88 |
| 52 Week High | $165.39 | $79.95 |
| Indicator | JJSF | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 71.50 |
| Support Level | $89.94 | $63.23 |
| Resistance Level | $95.73 | $66.77 |
| Average True Range (ATR) | 1.95 | 3.56 |
| MACD | 0.01 | 1.45 |
| Stochastic Oscillator | 39.95 | 99.92 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.